home / stock / cerc / cerc short
Short Information | Cerecor Inc. (NASDAQ:CERC)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 969,298 |
Total Actual Volume | 7,471,709 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 48,465 |
Average Short Percentage | 12.83% |
Is there a CERC Short Squeeze or Breakout about to happen?
See the CERC Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
08-25-2021 | $2.98 | $2.93 | $2.98 | $2.9 | 266,862 | 18,954 | 7.1% |
08-24-2021 | $2.88 | $2.98 | $3 | $2.88 | 401,043 | 28,187 | 7.03% |
08-23-2021 | $2.82 | $2.89 | $2.93 | $2.7711 | 256,800 | 18,885 | 7.35% |
08-20-2021 | $2.62 | $2.77 | $2.83 | $2.62 | 376,450 | 56,071 | 14.89% |
08-19-2021 | $2.8 | $2.65 | $2.8893 | $2.61 | 419,575 | 72,789 | 17.35% |
08-18-2021 | $2.79 | $2.78 | $2.87 | $2.72 | 207,544 | 39,989 | 19.27% |
08-17-2021 | $2.73 | $2.79 | $2.81 | $2.6899 | 272,871 | 44,948 | 16.47% |
08-16-2021 | $2.84 | $2.77 | $2.87 | $2.66 | 421,880 | 62,443 | 14.8% |
08-12-2021 | $3.02 | $2.93 | $3.03 | $2.9 | 407,562 | 56,598 | 13.89% |
08-11-2021 | $2.96 | $3.06 | $3.06 | $2.88 | 472,972 | 74,974 | 15.85% |
08-10-2021 | $2.98 | $2.96 | $3.1 | $2.95 | 339,852 | 83,137 | 24.46% |
08-09-2021 | $2.88 | $3.02 | $3.05 | $2.8302 | 532,098 | 79,667 | 14.97% |
08-06-2021 | $2.82 | $2.82 | $2.89 | $2.74 | 472,857 | 91,649 | 19.38% |
08-05-2021 | $2.66 | $2.82 | $2.82 | $2.66 | 404,827 | 37,097 | 9.16% |
08-04-2021 | $2.67 | $2.68 | $2.76 | $2.61 | 537,893 | 44,909 | 8.35% |
08-03-2021 | $2.66 | $2.69 | $2.73 | $2.63 | 341,825 | 59,511 | 17.41% |
08-02-2021 | $2.66 | $2.69 | $2.7899 | $2.65 | 320,474 | 19,772 | 6.17% |
07-30-2021 | $2.68 | $2.66 | $2.72 | $2.64 | 351,724 | 45,013 | 12.8% |
07-29-2021 | $2.75 | $2.69 | $2.805 | $2.69 | 301,825 | 6,501 | 2.15% |
07-28-2021 | $2.72 | $2.75 | $2.845 | $2.68 | 364,775 | 28,204 | 7.73% |
News, Short Squeeze, Breakout and More Instantly...
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeut...
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financ...
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-00...